Second Ward of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Future Oncol. 2024;20(30):2293-2302. doi: 10.1080/14796694.2024.2386929. Epub 2024 Sep 5.
Wilms tumor (WT) is the most common malignant tumor of the urinary system in children. Though the traditional treatment of surgery plus radiotherapy and chemotherapy achieves exciting clinical efficacy, in relapsed and refractory cases, the long-term overall survival rates are poor. Besides, chemotherapy and radiation have serious long-term toxic side effects on children. Cancer immunotherapy is a new tumor therapy that works by activating the body's immune system to allow immune cells to kill tumor cells more efficiently. Currently, cancer immunotherapy has been tested in clinical trials or basic studies in WT. This article reviews the current status of clinical trials and basic research of cancer immunotherapy in WT to promote the application of cancer immunotherapy in WT patients.
威尔姆斯瘤(WT)是儿童泌尿系统最常见的恶性肿瘤。尽管手术加放化疗的传统治疗方法取得了令人兴奋的临床疗效,但在复发和难治性病例中,长期总体生存率仍较差。此外,化疗和放疗对儿童有严重的长期毒性副作用。癌症免疫疗法是一种新的肿瘤治疗方法,通过激活机体的免疫系统,使免疫细胞更有效地杀死肿瘤细胞。目前,癌症免疫疗法已在 WT 中进行了临床试验或基础研究。本文综述了 WT 中癌症免疫疗法的临床研究和基础研究现状,以促进癌症免疫疗法在 WT 患者中的应用。